Although activation of the TMM has been shown to be a key factor in the poor prognosis of neuroblastoma, MYCN amplification and ATRX mutations, the primary drivers of the TMM, are also associated with multiple modes of transcriptional activation that drive malignant transformation. The gene discussed is MYCN; the disease is neuroblastoma.